infliximab + methylprednisolone + methotrexate

This is a combination therapy consisting of three medications: **Infliximab**: A chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-α) that blocks both soluble and transmembrane forms of TNF-α. It is administered as an intravenous infusion typically every 6-8 weeks. **Methylprednisolone**: A synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. **Methotrexate**: An antimetabolite and antifolate drug that inhibits dihydrofolate reductase, interfering with DNA synthesis and cellular replication. This combination is commonly used in treating autoimmune inflammatory conditions, particularly rheumatoid arthritis, where methotrexate is often co-administered with infliximab to improve efficacy and reduce immunogenicity of the biologic agent. Methylprednisolone may be used to manage acute flares or as premedication before infliximab infusions to reduce infusion reactions.